Descriptive analysis of the use of ipilimumab (IPI) in previously treated patients with unresectable stage III or IV metastatic melanoma (MM) in four university hospitals of Quebec, Canada.

e21020Background: IPI was approved in Quebec in 2012 for treatment of mm patients with an ECOG of 0-1 after failure to chemotherapy. We measured the clinical benefit and adverse events (AE) profile...